Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Drug Screening Using IMD in Bladder Cancer
- Status
- ENROLLING_BY_INVITATION
- Phase
- EARLY_PHASE1
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Status
- TERMINATED
- Phase
- PHASE1
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
- Status
- COMPLETED
- Phase
- N/A
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
- Status
- RECRUITING
- Phase
- PHASE4
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1